• Profile
Close

Predictive factors and long-term visual outcomes after anti-vascular endothelial growth factor treatment of retinal angiomatous proliferation

Clinical Ophthalmology Oct 11, 2019

Maruyama-Inoue M, et al. - In this retrospective observational study, researchers reported findings of 9-year follow-up examinations and predictive factors for visual acuity outcome following intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents to treat retinal angiomatous proliferation (RAP). The study sample consisted of 85 treatment-naïve eyes in 61 patients (mean age was 84.0 years) treated with intravitreal injections of anti-VEGF agents. As an induction treatment, all patients are given three consecutive monthly injections. Data reported that the mean BCVA gradually reduced from 0.58 at baseline to 0.70 at 36 months, 0.82 at 48 months, and 0.92 at 108 months. Baseline visual acuity and central foveal thickness were associated with visual acuity improvement at the final visits. With the use of intravitreal injections of anti-VEGF agents, it was difficult to achieve long-term stabilization of vision in RAP patients, regardless of treatment modality. In order to maintain visual acuity in patients with RAP, earlier diagnosis and treatment are necessary.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay